Irish heart-drug developer Amarin Corp. PLC, with research operations in Stonington, says its Vascepa synthetic fish-oil pill is about to collect a pair of U.S. patents.
The U.S. Patent & Trademark Office has published notice of intent to issue a pair of patents for indications stemming from Vascepa's "surprising and unexpected'' results in Amarin's "Marine'' trial this summer, said Amarin Chairman and CEO Joseph Zakrzewski.
The notices mean patent authorities have determined Amarin's intellectual property warrants patent protection.
The issued patent would be valid until at least 2030 and will be formally listed in the Food & Drug Administration's "orange book,'' officials said. The FDA approved Vascepa for prescription use in July.
So far, Amarin says it has collected or stands to collect a half-dozen patents, and has applications pending for more than 25 more on Vascepa and other cardiovascular drugs in the U.S. and in Europe.
Amarin's operational headquarters are in Bedminster, N.J.